Breaking News: Fennec Pharmaceuticals Receives European Commission Approval for Pedmarqsi – A Groundbreaking Solution to Reduce Hearing Loss in Pediatric Cancer Patients
Fennec Pharmaceuticals Announces Approval for Pedmarqsi™ in the European Union New Therapy for Reducing Cisplatin-induced Hearing Loss in Pediatric Patients Research Triangle Park, N.C., June 06, 2023 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) has recently made a groundbreaking announcement regarding their latest development in pediatric oncology treatment. The company has introduced…